For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- COPD Treatments, Smoking Cessation Aids to Show Double-Digit Growth: Fuji-Keizai
November 1, 2010
- Mediscience: FY2010 Business Results Fall Short of Forecasts
November 1, 2010
- IMSUT Objects to Asahi Shimbun News
November 1, 2010
- JMA, JAMS Oppose JSLN's Cholesterol GL for Longevity
November 1, 2010
- BI Inaugurates New Inhaler Factory
November 1, 2010
- Japan Can Contribute to Global Development by Earlier Participation: Dr Yoshikawa of Eli Lilly Japan
November 1, 2010
- 5-Fold Increase in Pollen Counts Expected in Spring 2011
November 1, 2010
- Japan's First IP Fund Starts Operation
November 1, 2010
- Diagnostic Imaging Is Japan's Advantage: Ms Sawada of Shionogi
November 1, 2010
- Catalent Embarks on Master Cell Bank Development Business in Japan
November 1, 2010
- Vidaza Recommended for Approval
November 1, 2010
- “Medical Innovation Center Scheme”Proposed by Dr Kayama
November 1, 2010
- Takeda to Accelerate Business Development in China
November 1, 2010
- US FDA Issues Warning to Kyowa Hakko Bio
November 1, 2010
- New Tools Expected to Be Useful for Drug Development: Dr Uyama of PMDA
November 1, 2010
- Prime Minister Kan Calls on Industry to Invest More in Japan
November 1, 2010
- Healthcare, Nursing Care Drive Japan's Economic Growth: Health Minister Hosokawa
November 1, 2010
- Pharma Industry Contributes to Int'l Balance of Technical Fee Payments
November 1, 2010
- JPMA Issues Warning to MSD on Violation of Promotion Code
November 1, 2010
- Global Pharma Market to Reach US$880 Bil. in 2011: IMS Health
November 1, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…